In focus · trending topic

skindisease

35 stories · following the connections

Abeona Therapeutics Receives FDA Breakthrough Therapy Designation for EB-101 Autologous Cell Therapy in Epidermolysis Bullosa

By Nasdaq OMXAug 29, 2017, 1:05 PM UTC

Abeona Therapeutics Announces Appointment of Juan Ruiz as Chief Medical Officer

By Nasdaq OMXJul 25, 2017, 12:05 PM UTC

Abeona Therapeutics Receives Guidance from FDA to Commence Pivotal Phase 3 for EB-101 Gene Therapy for Patients with Epidermolysis Bullosa

By Nasdaq OMXJul 18, 2017, 12:05 PM UTC

Abeona Therapeutics Receives Rare Pediatric Disease Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa

By Nasdaq OMXMay 30, 2017, 12:32 PM UTC

Abeona Therapeutics Receives Rare Pediatric Disease Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa

By Nasdaq OMXMay 30, 2017, 12:32 PM UTC

Abeona Therapeutics Receives Rare Pediatric Disease Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa

By Nasdaq OMXMay 30, 2017, 12:32 PM UTC

Abeona Therapeutics Receives Rare Pediatric Disease Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa

By Nasdaq OMXMay 30, 2017, 12:32 PM UTC

Abeona Therapeutics Receives Rare Pediatric Disease Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa

By Nasdaq OMXMay 30, 2017, 12:32 PM UTC